NCT07908134
Study to Establish Safety, Tolerability and Pharmacokinetics of NRL-1049 in Healthy Adult Participants Following Multiple-Dose Administration
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Safety and tolerability: Treatment-emergent adverse events (TEAEs)
Timeframe: Predose on Day 1 until 72 hours following the last study drug administration on Day 7.
Arms and interventions
NRL-1049 50 mgActive comparator
2 × 25 mg IR capsules
NRL-1049 100 mgActive comparator
100 mg: (1 × 25 mg) + (1 x 75 mg) IR capsules
NRL-1049 150 mgActive comparator
150 mg: 2 × 75 mg IR capsules
NRL-1049 200 mgActive comparator
200 mg: (2 × 25 mg) + (2 × 75 mg) IR capsules
NRL-1049 250 mgActive comparator
250 mg: (1 × 25 mg) + (3 × 75 mg) IR capsules
PlaceboPlacebo comparator
Placebo-to-match NRL-1049 capsules (identical size and appearance as the respective NRL-1049 product strength)
Drugs: NRL-1049, Placebo